Checkpoint Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$41
$0
$6
$31
Gross Profit
-4,439
-8,497
-8,292
-5,465
EBITDA
-6,673
-10,948
-10,169
-7,701
EBIT
-10,991
-10,212
-15,402
Net Income
-6,670
-10,945
-19,128
-5,724
Net Change In Cash
41
0
6
31
Free Cash Flow
-6,240
-6,474
-6,833
-14,750
Cash
4,951
11,241
4,928
1,772
Basic Shares
36,526
32,930
27,285
19,988

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$103
$192
$268
$1,069
Gross Profit
-43,463
-49,633
268
1,069
EBITDA
-52,148
-53,882
-56,670
-23,201
EBIT
-52,315
-58,333
-56,723
-23,201
Net Income
-51,847
-66,915
-56,617
-22,961
Net Change In Cash
103
192
268
1,069
Cost of Revenue
13,963
14,695
Free Cash Flow
-47,590
-57,554
-26,306
-16,551
Cash
4,928
12,068
54,735
40,772
Basic Shares
18,742
8,835
7,603
5,583

Earnings Calls

Quarter EPS
2024-06-30
-$0.18
2024-03-31
-$0.33
2023-12-31
-$1.10
2023-09-30
-$0.29